10.18453/rosdok_id00005800 Su, Zhaoran Zhaoran Su http://d-nb.info/gnd/1419719106 Universität Rostock 2025 570 Life science 610 Medical sciences Medicine 2025 en https://purl.uni-rostock.de/rosdok/id00005800 urn:nbn:de:gbv:28-rosdok_id00005800-2 Colorectal cancer (CRC) shows heterogeneous responses to Tumor Treating Fields (TTF), a non-invasive therapy disrupting mitosis. In 21 CRC cell lines, TTF induced microtubule disruption, mitotic defects, metabolic stress, DNA damage, and apoptosis. NAALADL1 was upregulated in resistant cells; its knockdown enhanced TTF sensitivity by stabilizing microtubules and inducing G2/M arrest. Virtual screening identified Lumacaftor and Bestatin as synergistic with TTF, highlighting NAALADL1 as a promising target for personalized CRC therapy.